(Q43276080)

18 November 2017

title

Pharmacokinetics and efficacy of a biweekly dosage formulation of exenatide in Zucker diabetic fatty (ZDF) rats (English)

1 reference

18 November 2017

1 reference

Hyun-Hee Kwak

1

1 reference

18 November 2017

Won-Sik Shim

2

1 reference

18 November 2017

Seongmee Hwang

3

1 reference

18 November 2017

Mi-Kyung Son

4

1 reference

18 November 2017

Yoon-Ji Kim

5

1 reference

18 November 2017

Tae-Hyoung Kim

6

1 reference

18 November 2017

Zee-Hye Yoon

7

1 reference

18 November 2017

Hyun-Jun Youn

8

1 reference

18 November 2017

Ghun-Il Lee

9

1 reference

18 November 2017

Soo-Hyoung Kang

10

1 reference

18 November 2017

Chang-Koo Shim

11

1 reference

18 November 2017

language of work or name

1 reference

11 September 2009

1 reference

18 November 2017

published in

Pharmaceutical Research

1 reference

18 November 2017

volume

26

1 reference

18 November 2017

issue

11

1 reference

18 November 2017

page(s)

2504-2512

1 reference

In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing 14C-labeled tetanus toxoid

18 November 2017

cites work

1 reference

12 December 2020

Poly(lactide-co-glycolide) microparticles for the development of single-dose controlled-release vaccines

1 reference

12 December 2020

Changes in glycated haemoglobin levels in diabetic rats measured with an automatic affinity HPLC

1 reference

12 December 2020

Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas

1 reference

12 December 2020

Impurity formation studies with peptide-loaded polymeric microspheres Part I. In vivo evaluation

1 reference

12 December 2020

Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.

1 reference

12 December 2020

Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro

1 reference

12 December 2020

The role of incretins in glucose homeostasis and diabetes treatment

1 reference

12 December 2020

Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes

1 reference

12 December 2020

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

1 reference

12 December 2020

Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells.

1 reference

12 December 2020

Exenatide: clinical aspects of the first incretin-mimetic for the treatment of type 2 diabetes mellitus

1 reference

12 December 2020

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

1 reference

12 December 2020

Dose-response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats

1 reference

12 December 2020

Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures

1 reference

12 December 2020

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

1 reference

12 December 2020

GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes

1 reference

12 December 2020

Both Subcutaneously and Intravenously Administered Glucagon-Like Peptide I Are Rapidly Degraded From the NH2-Terminus in Type II Diabetic Patients and in Healthy Subjects

1 reference

12 December 2020

Glycohemoglobin: a primary predictor of the development or reversal of complications of diabetes mellitus.

1 reference

12 December 2020

The effect of physiological levels of glucagon-like peptide-1 on appetite, gastric emptying, energy and substrate metabolism in obesity

1 reference

12 December 2020

10.1007/S11095-009-9966-3

Identifiers

DOI

1 reference

18 November 2017

1 reference